Tepezza

Tepezza (teprotumumab-trbw) is an insulin-like growth factor-1 receptor inhibitor used to treat Thyroid Eye Disease, an autoimmune disease characterized by proptosis (a condition where the eyes are pushed forward and bulge outward) leading to eye pain double vision and difficulty closing the eyelid.

ICPA participated in clinical trials of Tepezza and began administering the drug on the first day it was commercially available in March, 2020.